Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors-Reference-Cited by-同舟云学术

Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors

Author:

Ito Kouta¹²,Chapman Rick³,Pearson Steven D.³,Tafazzoli Ali⁴,Yaffe Kristine⁵⁶,Gurwitz Jerry H.¹²

Affiliation:

1. Meyers Primary Care Institute, a joint endeavor of University of Massachusetts Medical School, Reliant Medical Group, and Fallon Health, Worcester

2. Division of Geriatric Medicine, University of Massachusetts Medical School, Worcester

3. Institute for Clinical and Economic Review, Boston, Massachusetts

4. Evidera, Bethesda, Maryland

5. Department of Psychiatry, Neurology, and Epidemiology and Biostatistics, University of California, San Francisco

6. San Francisco VA Medical Center, San Francisco, California

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

Reference44 articles.

2. Preclinical Alzheimer disease drug development: early considerations based on phase 3 clinical trials.;Hung;J Manag Care Spec Pharm,2020

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Errors in Simulation Model;JAMA Network Open;2024-08-16